Sonrotoclax and Zanubrutinib With CAR-T in Mantle Cell Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional study evaluates the safety and potential benefit of combining sonrotoclax, a BCL-2 inhibitor, with zanubrutinib, a BTK inhibitor, alongside standard CAR-T cell therapy in relapsed or refractory mantle cell lymphoma. Eligible participants must be planned for CAR-T therapy and meet typical health and disease criteria, including measurable disease and prior lines of therapy. The regimen starts with zanubrutinib, followed by a ramp-up of sonrotoclax plus zanubrutinib during induction, then CAR-T infusion, and maintenance zanubrutinib. Treatment effects will be followed over time, with ongoing post-treatment monitoring until results are fully known.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have histologically confirmed mantle cell lymphoma that is relapsed or refractory after at least one prior line of systemic therapy
* Eligible for and planned to receive Health Canada approved CAR-T.
* Have a formalin fixed paraffin embedded tumour tissue block available and must have provided informed consent for the release of the block.
* Presence of radiologically documented disease.
* Measurable disease (one site bidimensionally measurable).
* Age ≥ 18 years.
* Have an ECOG performance status of 0, 1 or 2
* Anticipated life expectancy of ≥ 6 months
* Adequate hematologic and biochemical parameters
* Must have received prior systemic therapy as shown below;
* At least one line of systemic therapy including a Bruton's Tyrosine Kinase inhibitor (BTKi).
* Participants who have previously received venetoclax, sonrotoclax, or any other BCL2 inhibitor (BCL2i) are eligible as long as progressive disease did not occur within 6 months of the last dose of BCL2i. Participants with progressive disease during BCL2i therapy or within 6 months of last dose are not eligible.
* Participants must enter the study while on a BTKi or enroll to a substudy of the protocol to receive zanubrutinib for a minimum duration prior to enrolling to the main study.
* Participants previously exposed to zanubrutinib are eligible irrespective of response to treatment.
* Participants entering the study while on a BTKi must have their BTKi switched to zanubrutinib supplied through the study.
* Participants must have recovered to ≤ grade 1 from all reversible toxicity related to prior therapies.
* Adequate washout must be followed per protocol.
* Prior high-dose myelosuppresive radiation is permitted ≥28 prior to enrollment.
* Previous major surgery is permitted ≥28 days prior to enrollment. Participants of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria

* • Participants on active anticancer therapy for other advanced or metastatic malignancies.
* Concurrent treatment with other anti-cancer therapy
* Serious illnesses or medical conditions which would not permit the participant to be managed according to the protocol.
* Known hypersensitivity to the study drug(s) or their components.
* Prior CD19-directed CAR-T at any time, autologous hematopoietic cell transplantation within 6 weeks, or allogeneic hematopoietic cell transplantation within 3 months. Allogeneic hematopoietic cell transplantation recipients must be free of clinically-significant graft-versus-host disease (GvHD) and must be off immunosuppression for GvHD for at least 4 weeks before enrollment.
* Untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac dysfunction (including cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects) or unstable angina congestive heart failure or myocardial infarction within the previous year.
* Active, uncontrolled bacterial, fungal, or viral infection within 14 days prior to enrollment
* Pregnant or breastfeeding women.
* Inability to discontinue use of moderate or strong CYP3A inducers or inhibitors during the ramp-up treatment period with sonrotoclax.
* Live vaccination within 4 weeks prior to enrollment or who plan to receive a live vaccine during treatment or within 90 days post last dose.
* Inability to swallow capsules or tablets or have any diseases significantly affecting GI function
* Active central nervous system (CNS) disease; Participants with stable CNS disease are eligible.
* Growth factors within 28 days prior to enrollment.

Where it's running

• Arthur J.E. Child Comprehensive Cancer Centre
  Calgary, Alberta, Canada Recruiting
• Cross Cancer Institute
  Edmonton, Alberta, Canada Recruiting
• BCCA - Vancouver
  Vancouver, British Columbia, Canada Recruiting
• Juravinski Cancer Centre at Hamilton Health Sciences
  Hamilton, Ontario, Canada Recruiting
• University Health Network
  Toronto, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Annette Hay
• Email: ahay@ctg.queensu.ca
• Phone: 613-533-6430

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Glofitamab for mantle cell lymphoma after CAR-T failure

  This phase 2, multicenter, single-arm study tests glofitamab in adults with mantle cell lymphoma who did not respond to or relapsed after CAR-T cell therapy.

  Recruiting Phase 2 Fondazione Italiana Linfomi - ETS · Alessandria and 13 other locations · NCT07453095

• Obinutuzumab plus zanubrutinib and lenalidomide as first treatment for mantle cell lymphoma

  This trial will test whether a combination of obinutuzumab, zanubrutinib, and lenalidomide (with CAR‑T offered for high‑risk patients) works as a first‑line option for people newly diagnosed with mantle cell lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07261163

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.